All In Biotech

Drug Trial Radar · NCT07239986

A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma

An Open-label, Multicenter Phase 2 Clinical Study on the Efficacy and Safety of BB102 in Patients With Advanced or Unresectable FGF19-overexpressing Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Dec 2025

Primary completion

Jun 2027

Study completion Jun 2028

Sponsor

Lead sponsor
Broadenbio Ltd., Co.Industry
Sponsor type
Industry
First posted
Nov 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 study to evaluate the efficacy and safety of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced or unresectable FGF19-overexpressing hepatocellular carcinoma. This study has two phase: dose escalation phase and expansion phase.

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

  • BB102Drug

    Oral BB102 Tablets in two dosage

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: From enrollment to the end of treatment assessed up to 12 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of University of Science and Technology of China

    Hefei, Anhui, China

  • Zhongshan Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.